Pulmonary Arterial Hypertension Disease Summary

Last updated: 17 March 2026

Overview

Pulmonary arterial hypertension (PAH) is part of the spectrum of pulmonary hypertension which is a hemodynamic and pathophysiological condition, as stated in the Introduction section. The different types of pulmonary hypertension based on the mean PA pressure are enumerated in this section.

Pulmonary hypertension affects approximately 1% of the global population. A detailed discussion about the prevalence of pulmonary hypertension is in the Epidemiology section.

The Pathophysiology section states that PAH is a syndrome resulting from restricted flow through the pulmonary arterial (PA) circulation, resulting in increased pulmonary vascular resistance and remodeling, and ultimately leading to right heart failure. 



Pulmonary Arterial Hypertension_Disease SummaryPulmonary Arterial Hypertension_Disease Summary




The Risk Factors section lists the different risk factors and associated conditions for PAH.

In the Classification section, PAH is classified under different groups depending on the cause.

History and Physical Examination

The Clinical Presentation section enumerates the typical symptoms of PAH. The signs seen in PAH are listed in the Physical Examination.

Diagnosis

The Screening section discusses the recommendation as regards to at-risk individuals for early diagnosis, initiation of treatment and improvement of prognosis of patients with PAH.

Discussion on non-invasive and invasive diagnostic tests for the detection of pulmonary hypertension is in the Laboratory Tests and Ancillaries and Imaging sections.  Diagnostic tests for pulmonary hypertension clinical classification and determination of associated causes of PAH are also enumerated in this section.

As the symptoms of PAH may overlap with other diseases, it is important to rule them out. Conditions that should be considered are listed in the Differential Diagnosis section.

Management

Clinical and hemodynamic assessments for the determination of prognosis and management of PAH are discussed in the Evaluation section.

The treatment goal and strategy in patients with PAH are stated in the Principles of Therapy section.

The Pharmacological Therapy section discusses in detail the treatment options in patients with PAH, whether with positive or negative acute vasoreactivity. Options for monotherapy, combination therapy and supportive therapy are also explained in this section.

The Nonpharmacological section includes general care and things to educate the patient about the management of PAH.

Interventional therapies such as balloon atrial septostomy (BAS), Potts shunt and lung transplantation are in the Surgery section.

The Monitoring section identifies follow-up recommendations and assessments of patients with PAH based on the patient’s history and clinical status.